Years after the biopharmaceutical industry stepped up to create COVID-19 vaccines as the virus spiraled into a global ...

Healthcare stocks have been out of vogue with investors since late 2022. Myriad reasons underlie the negative sentiment ...

Pfizer’s PFE stock has risen 5.9% in the past three months. The stock has started to show a consistent increase, with some ups and downs in between, after it took a hammering in the past couple of ...

Moderna has filed complaints in the US and Germany claiming that the mRNA technology used to make Pfizer and BioNTech's Comirnaty vaccine infringes multiple patents that cover its own Spikevax shot.

Pfizer's stock has recently struggled but remains a bargain with generous dividends. Is now a good time to invest in PFE?

Pfizer and BioNTech earned more than $3.3 billion in revenue from global sales of their vaccine Comirnaty last year, while Moderna earned $3.2 billion from its vaccine Spikevax, according to ...

What are Pfizer's top-selling medications/vaccines? They are Comirnaty, Eliquis, Prevnar family, Vyndaqel family and Ibrance. Their total sales were $9.41 billion in the last three months of 2024 ...

Equities research analysts at Zacks Research reduced their Q2 2026 earnings per share (EPS) estimates for Pfizer in a report issued on Thursday, March 20th. Zacks Research analyst K. Shah now ...

Pfizer reported fourth-quarter 2024 adjusted ... in the quarter to $4.28 billion due to lower spending behind the marketing of Comirnaty and Paxlovid, partially offset by an increase in spending ...

Pfizer faces near-term challenges as COVID-19 product sales decline. However, excluding Comirnaty and Paxlovid, revenue grew 12% operationally in full-year 2024. This result demonstrates the ...